The Nonclinical Studies Network is a key element in the successful development of U.S. medical countermeasures for biological threats, particularly since efficacy of products directed against most of these threats cannot be verified using clinical studies.
The U.S. government this month awarded multiple Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts to support this network of GLP laboratories to provide capabilities for nonclinical animal studies, analytical services, and toxicology services.
The following organizations were selected:
- Battelle Memorial Institute
- IIT Research Institute
- Lovelace Biomedical & Environmental Research Institute
- MRI Global
- Public Health England
- Southern Research Institute
- SRI International
The effort is on behalf of the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness & Response (ASPR).
BARDA anticipates that contracts awarded from under this ID/IQ will serve to facilitate the animal model development of medical countermeasures and supportive reagents and assays for regulatory acceptance in the U.S.
